Alnylam Pharmaceuticals (ALNY) PT Lowered to $302 at BofA Securities
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $228.61 +1.79%
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
BofA Securities analyst Tazeen Ahmad lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $302.00 (from $315.00) while maintaining a Buy rating.
You May Also Be Interested In
- BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
- Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at H.C. Wainwright
- Suncrete Inc (RMIX) PT Lowered to $22 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
